SCYNEXIS, Inc. Shareholders' Equity
SCYNEXIS, Inc. (SCYX) had Shareholders' Equity of $66.93 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $66.93M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $41.31M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $49.38M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $36.43M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $66.93M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $41.31M 10-Q · filed 2026-08-10 |
| 2025-12-31 | $49.38M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $36.43M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $44.47M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $50.53M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $55.08M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $58.53M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $60.41M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $74.11M 10-Q · filed 2025-08-13 |
| 2023-12-31 | $72.96M 10-K · filed 2026-03-04 |
| 2023-09-30 | $91.99M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $93.08M 10-Q · filed 2024-11-06 |
| 2023-03-31 | -$29.91M 10-Q · filed 2024-08-08 |
| 2022-12-31 | $3.23M 10-K · filed 2025-03-12 |
| 2022-09-30 | $17.21M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $45.48M 10-Q · filed 2023-11-13 |
| 2022-03-31 | $38.93M 10-Q · filed 2023-08-14 |
| 2021-12-31 | $41.26M 10-K · filed 2024-03-28 |
| 2021-09-30 | $37.61M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $32.32M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $25.92M 10-Q · filed 2022-08-15 |
| 2020-12-31 | $22.76M 10-K · filed 2023-03-31 |
| 2020-09-30 | $9.56M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $6.33M 10-Q · filed 2021-11-10 |
| 2020-03-31 | $6.46M 10-Q · filed 2021-08-16 |
| 2019-12-31 | $12.89M 10-K · filed 2022-03-29 |
| 2019-09-30 | $6.14M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $10.40M 10-Q · filed 2020-11-06 |
| 2019-03-31 | $11.33M 10-Q · filed 2020-08-10 |
| 2018-12-31 | $31.23M 10-K · filed 2021-03-29 |
| 2018-09-30 | $27.88M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $26.55M 10-Q · filed 2019-11-12 |
| 2018-03-31 | $36.84M 10-Q · filed 2019-08-07 |
| 2017-12-31 | $21.41M 10-K · filed 2020-03-11 |
| 2017-09-30 | $27.26M 10-Q · filed 2018-11-13 |
| 2017-06-30 | $31.66M 10-Q · filed 2018-11-13 |
| 2017-03-31 | $33.53M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $34.82M 10-K · filed 2019-03-14 |
| 2016-09-30 | $33.18M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $43.88M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $35.04M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $41.95M 10-K · filed 2018-03-13 |
| 2015-09-30 | $49.97M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $56.77M 10-Q · filed 2015-08-19 |
| 2015-03-31 | $27.44M 8-K · filed 2015-10-30 |
| 2014-12-31 | $33.43M 10-K · filed 2017-03-13 |
| 2014-09-30 | $36.14M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $39.42M 10-Q · filed 2014-08-13 |
| 2014-03-31 | -$109.22M 10-Q/A · filed 2014-07-11 |
| 2013-12-31 | -$108.11M 10-K · filed 2017-03-13 |
| 2012-12-31 | -$65.42M 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |